section name header

Pronunciation

dap-a-gli-FLOE-zin

Classifications

Therapeutic Classification: antidiabetics

Pharmacologic Classification: sodium-glucose co-transporter 2 (SGLT2) inhibitors

Indications

BEERS REMS


Action

  • Inhibits proximal renal tubular sodium-glucose cotransporter 2 (SGLT2), which determines reabsorption of glucose from the tubular lumen. Inhibits reabsorption of glucose, lowers renal threshold for glucose, and increases excretion of glucose in urine.
Therapeutic effects:
  • Improved glycemic control.
  • Reduction in risk of HF hospitalizations in patients with type 2 diabetes mellitus.
  • Reduction in risk of cardiovascular death, HF hospitalizations, and urgent visits for HF in patients with HF.
  • Reduction in risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and HF hospitalizations in patients with chronic kidney disease at risk of progression.

Pharmacokinetics

Absorption: 78% absorbed following oral administration.

Distribution: Unknown.

Metabolism/Excretion: Extensively metabolized by UGT1A9 to inactive metabolites, which are primarily excreted in urine. 15% excreted in feces as unchanged drug.

Half-Life: 12.9 hr

Time/Action Profile

( in A1c)
ROUTEONSETPEAKDURATION
POwithin 4 wk12 wkunknown





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Endo: hypoglycemia ( with other medications)

F and E: hyperphosphatemia, hypovolemia, KETOACIDOSIS

GU: urination, acute kidney injury, genital mycotic infections, NECROTIZING FASCIITIS OF PERINEUM (FOURNIER'S GANGRENE), renal impairment, urinary tract infection(including pyelonephritis), UROSEPSIS

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS OR ANGIOEDEMA)

Interactions

Drug-drug:

Route/Dosage

Type 2 Diabetes Mellitus (for Glycemic Control)

Renal Impairment

Type 2 Diabetes (for Reduction in Risk of HF Hospitalizations), HF, or Chronic Kidney Disease

Renal Impairment

Availability

(Generic available)

Assessment

Lab Test Considerations:

Toxicity and Overdose:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Farxiga

Canadian Brand Names

Forxiga